This study involving human subjects was conducted in compliance with the Declaration of Helsinki and approved by the Ethical Committee of The People's Hospital of Yingshang (Approval No. 2025-18). Written informed consent was obtained from all participants prior to their enrollment in the study, with detailed explanations provided regarding the study's objectives, procedures, potential risks, and benefits.
Study design
This was a prospective non-randomized single-center study. The study population consisted of 102 patients diagnosed with HICH according to the HICH diagnostic criteria8 admitted to our hospital between October 2023 and June 2025 (inclusive). The sample size was estimated using sample size software (G-Power 3.1), with an effect size of 0.3, α=0.05, power (1-β) =0.9, and dropout rate of 10%, indicating a minimum sample size of 93. A total of 102 patients were enrolled to ensure sufficient statistical power. Inclusion criteria: Diagnosed with spontaneous intracerebral hemorrhage by cranial CT/MRI; history of hypertension or systolic blood pressure ≥140 mmHg at admission; modified Rankin Scale (mRS) score ≤2 points within 3 months prior to onset9; Glasgow Coma Scale (GCS) score ≥8 at admission10. Exclusion criteria: secondary intracerebral hemorrhage due to trauma, aneurysm/vascular malformation, or tumor; severe liver or kidney dysfunction; pregnant or lactating women; prior thrombolytic therapy or craniectomy before admission; inability to cooperate with nursing interventions or expected survival <7 days. In this study, a total of 27 patients developed MODS, and these patients were grouped into the MODS group, while the other 75 patients were grouped into the control group.
Intervention
All patients received IKAP health education upon admission, including information dissemination (through videos and manuals explaining the causes, triggers, and hazards of HICH and electrolyte disorders), knowledge reinforcement (daily bedside mini-classes with personalized interpretations based on patient test results), attitude change (through case sharing to enhance patient compliance), and practical guidance (guiding family members to participate in blood pressure monitoring and nasogastric feeding management). Physical rehabilitation training is also provided: Acute phase (≤7 days): Passive joint exercises for upper limbs - shoulder abduction/adduction, elbow flexion/extension; lower limbs - hip flexion/extension, knee flexion/extension; 2x daily, 15 min per session with movement amplitude: 30°-60° for joints at a speed of 5-10 movements per min. Subacute phase (8-14 days): Seated balance training with 3 sets per session for 5 min per set, with support initially, and then gradually reducing support; bedside standing at 2x daily at 10-15 min per session, with a weight-bearing ratio of 30%-50% initially, increasing to 50%-70%. Recovery phase (≥15 days): Progressive walking training for 30 min daily at a speed of 30-40 m per min initially, increasing by 5 m per min weekly, and an intensity of target heart rate = 60%-70% of maximum heart rate. The staged exercise rehabilitation training lasts for a minimum of 15 consecutive days in total, including 7 days for the acute phase, 7 days for the subacute phase, and no less than 15 days for the recovery phase. The overall adherence rate to IKAP health education was 82.3% (84/102), defined as attending ≥80% of bedside mini classes. The adherence rate to exercise training was 78.4% (80/102), with ≥80% of scheduled sessions completed.
Sample collection and testing
For analysis, 2 mL of venous blood was collected from each patient on an empty stomach in the morning for complete blood count (including WBC, RBC, HGB, and CRP) using EDTA-K2 anticoagulant (purple cap vacuum tube). After collection, the sample was gently inverted and mixed 8x. Samples were stored at room temperature and tested within 2 h; if testing was delayed, samples were stored at 2-8 °C for no more than 4 h. A fully automatic blood analyzer was used for testing. System-compatible control materials (low, normal, and high values) were run before testing each day, with a coefficient of variation (CV%) set below 2.0%.
For electrolyte testing (including Ca²⁺, Cl⁻, Na⁺, and K⁺), 3 mL of venous blood was collected using a gel-separated coagulation tube (yellow cap). The blood was allowed to stand for 30 min before being centrifuged at 3,000 x g for 10 min. Anticoagulants containing EDTA, citrate, or oxalate were avoided to prevent interference. The separated serum was transferred to microcentrifuge tubes and stored at -20 °C for no more than 1 week, with repeated freezing and thawing prohibited. Testing was performed using a fully automated biochemical analyzer, and high and low-range quality control was conducted daily before testing.
For liver and kidney function, 3 mL of venous blood was collected using a gel-coated tube (yellow cap) for the assessment of albumin (ALB), alkaline phosphatase (ALP), total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), blood urea nitrogen (BUN), serum creatinine (sCr), and urinalysis (UA). The blood was allowed to stand for 30 min followed by centrifugation at 3,000 x g for 10 min at room temperature. A fully automated biochemical analyzer was utilized for testing, with quality control implemented according to Westgard multiple rules (1₃s/2₂s/R₄s/4₁s/1₀x)11. When quality control was out of range, alternative control materials, including third-party certified high and low concentration quality control sera (purchased from Randox Laboratories, UK), were activated. After switching to alternative controls, the calibration of the biochemical analyzer was repeated using the manufacturer's standard calibrator, and the validity of the alternative controls was verified by comparing the measured values with the target reference ranges before formal sample testing resumed.
Observation indicators
Changes in blood count, electrolytes, liver function, and kidney function before and after patient care were assessed. In addition, the incidence of MODS during patient care was statistically analyzed12. MODS was diagnosed based on the Sequential Organ Failure Assessment (SOFA) score, with a score ≥2 points in at least one organ system indicating MODS. Based on the above indicators, relevant factors affecting MODS were analyzed, and a risk prediction model was established.
Statistical analysis
Statistical analysis was performed using SPSS 24.0 software. For categorical data [n (%)], comparisons were made using the chi-square test. For continuous data, after confirming normal distribution via the Shapiro-Wilk test, values were recorded as (x ± s). The Shapiro-Wilk test showed that all continuous variables had P>0.05 (range: 0.123-0.876), indicating normal distribution. Bonferroni correction was used for multiple comparisons to control Type I errors. Intra-group comparisons (before vs. after) were performed using paired t-tests; inter-group comparisons (MODS group vs. control group) were conducted using independent sample t-tests. Non-parametric tests (Mann-Whitney U test) were used if the data did not meet normal distribution. Related factors were analyzed using logistic regression analysis. The risk model was based on the results of the logistic regression analysis, selecting independent factors influencing MODS to establish a combined formula, which was validated using a ROC curve. P<0.05 indicated statistically significant differences.